Akademska digitalna zbirka SLovenije - logo

Search results

Basic search    Expert search   

Currently you are NOT authorised to access e-resources SI consortium. For full access, REGISTER.

1 2 3 4 5
hits: 151
1.
  • Intermediate-risk meningiom... Intermediate-risk meningioma: initial outcomes from NRG Oncology RTOG 0539
    Rogers, Leland; Zhang, Peixin; Vogelbaum, Michael A ... Journal of neurosurgery, 07/2018, Volume: 129, Issue: 1
    Journal Article
    Peer reviewed
    Open access

    OBJECTIVE This is the first clinical outcomes report of NRG Oncology RTOG 0539, detailing the primary endpoint, 3-year progression-free survival (PFS), compared with a predefined historical control ...
Full text
Available for: UL

PDF
2.
  • Gliadel wafer implantation ... Gliadel wafer implantation combined with standard radiotherapy and concurrent followed by adjuvant temozolomide for treatment of newly diagnosed high-grade glioma: a systematic literature review
    Ashby, Lynn S; Smith, Kris A; Stea, Baldassarre World journal of surgical oncology, 2016-Aug-24, 2016-8-24, 20160824, Volume: 14, Issue: 1
    Journal Article
    Peer reviewed
    Open access

    Since 2003, only two chemotherapeutic agents, evaluated in phase III trials, have been approved by the US Food and Drug Administration for treatment of newly diagnosed high-grade glioma (HGG): ...
Full text
Available for: IZUM, KILJ, NUK, PILJ, PNG, SAZU, UL, UM, UPUK

PDF
3.
  • Phase III Randomized Trial ... Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma
    BATCHELOR, Tracy T; MULHOLLAND, Paul; DEGROOT, John ... Journal of clinical oncology, 09/2013, Volume: 31, Issue: 26
    Journal Article
    Peer reviewed
    Open access

    A randomized, phase III, placebo-controlled, partially blinded clinical trial (REGAL Recent in in Glioblastoma Alone and With Lomustine) was conducted to determine the efficacy of cediranib, an oral ...
Full text
Available for: NUK, UL, UM, UPUK

PDF
4.
  • An extent of resection thre... An extent of resection threshold for recurrent glioblastoma and its risk for neurological morbidity
    Oppenlander, Mark E; Wolf, Andrew B; Snyder, Laura A ... Journal of neurosurgery 120, Issue: 4
    Journal Article
    Peer reviewed
    Open access

    Despite improvements in the medical and surgical management of patients with glioblastoma, tumor recurrence remains inevitable. For recurrent glioblastoma, however, the clinical value of a second ...
Full text
Available for: UL
5.
  • Rindopepimut with Bevacizum... Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial
    Reardon, David A; Desjardins, Annick; Vredenburgh, James J ... Clinical cancer research, 04/2020, Volume: 26, Issue: 7
    Journal Article
    Peer reviewed
    Open access

    Rindopepimut is a vaccine targeting the tumor-specific EGF driver mutation, EGFRvIII. The ReACT study investigated whether the addition of rindopepimut to standard bevacizumab improved outcome for ...
Full text
Available for: CMK, NUK, UL, UM, UPUK

PDF
6.
  • An extent of resection thre... An extent of resection threshold for seizure freedom in patients with low-grade gliomas
    Xu, David S; Awad, Al-Wala; Mehalechko, Chad ... Journal of neurosurgery, 04/2018, Volume: 128, Issue: 4
    Journal Article
    Peer reviewed

    OBJECTIVE Seizures are the most common presenting symptom of newly diagnosed WHO Grade II gliomas (low-grade glioma LGG) and significantly impair quality of life. Although gross-total resection of ...
Full text
Available for: UL
7.
  • A randomized phase II study... A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG Oncology RTOG 0913
    Chinnaiyan, Prakash; Won, Minhee; Wen, Patrick Y ... Neuro-oncology, 04/2018, Volume: 20, Issue: 5
    Journal Article
    Peer reviewed
    Open access

    This phase II study was designed to determine the efficacy of the mammalian target of rapamycin (mTOR) inhibitor everolimus administered daily with conventional radiation therapy and chemotherapy in ...
Full text
Available for: NUK, UL, UM, UPUK

PDF
8.
  • Joint Final Report of EORTC... Joint Final Report of EORTC 26951 and RTOG 9402: Phase III Trials With Procarbazine, Lomustine, and Vincristine Chemotherapy for Anaplastic Oligodendroglial Tumors
    Lassman, Andrew B; Hoang-Xuan, Khê; Polley, Mei-Yin C ... Journal of clinical oncology, 08/2022, Volume: 40, Issue: 23
    Journal Article
    Peer reviewed
    Open access

    JCO Anaplastic oligodendroglial tumors (AOTs) are chemotherapy-sensitive brain tumors. We report the final very long-term survival results from European Organization for the Research and Treatment of ...
Full text
Available for: NUK, UL, UM, UPUK
9.
  • Association of MGMT Promoter Methylation Status With Survival Outcomes in Patients With High-Risk Glioma Treated With Radiotherapy and Temozolomide: An Analysis From the NRG Oncology/RTOG 0424 Trial
    Bell, Erica H; Zhang, Peixin; Fisher, Barbara J ... JAMA oncology, 10/2018, Volume: 4, Issue: 10
    Journal Article
    Peer reviewed
    Open access

    The initial report of NRG Oncology/Radiation Therapy Oncology Group (RTOG) 0424 demonstrated a 3-year overall survival benefit with the addition of temozolomide to radiotherapy compared with a ...
Check availability


PDF
10.
  • Low-risk meningioma: Initia... Low-risk meningioma: Initial outcomes from NRG Oncology/RTOG 0539
    Rogers, C Leland; Pugh, Stephanie L; Vogelbaum, Michael A ... Neuro-oncology (Charlottesville, Va.), 01/2023, Volume: 25, Issue: 1
    Journal Article
    Peer reviewed

    Three- and five-year progression-free survival (PFS) for low-risk meningioma managed with surgery and observation reportedly exceeds 90%. Herewith we summarize outcomes for low-risk meningioma ...
Full text
Available for: NUK, UL, UM, UPUK
1 2 3 4 5
hits: 151

Load filters